

# Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer

## Interdisziplinäre Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinie der DGGG und DKG (S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) – Teil 1 mit Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms



### Authors

Achim Wöckel<sup>1</sup>, Jasmin Festl<sup>1</sup>, Tanja Stüber<sup>1</sup>, Katharina Brust<sup>1</sup>, Stephanie Stangl<sup>2</sup>, Peter U. Heuschmann<sup>2</sup>, Ute-Susann Albert<sup>3</sup>, Wilfried Budach<sup>4</sup>, Markus Follmann<sup>5</sup>, Wolfgang Janni<sup>6</sup>, Ina Kopp<sup>3</sup>, Rolf Kreienberg<sup>6</sup>, Thorsten Kühn<sup>7</sup>, Thomas Langer<sup>5</sup>, Monika Nothacker<sup>3</sup>, Anton Scharl<sup>8</sup>, Ingrid Schreer<sup>9</sup>, Hartmut Link<sup>10</sup>, Jutta Engel<sup>11</sup>, Tanja Fehm<sup>12</sup>, Joachim Weis<sup>13</sup>, Anja Welt<sup>14</sup>, Anke Steckelberg<sup>15</sup>, Petra Feyer<sup>16</sup>, Klaus König<sup>17</sup>, Andrea Hahne<sup>18</sup>, Hans H. Kreipe<sup>19</sup>, Wolfram Trudo Knoefel<sup>20</sup>, Michael Denking<sup>21</sup>, Sara Brucker<sup>22</sup>, Diana Lüftner<sup>23</sup>, Christian Kubisch<sup>24</sup>, Christina Gerlach<sup>25</sup>, Annette Lebeau<sup>26</sup>, Friederike Siedentopf<sup>27</sup>, Cordula Petersen<sup>28</sup>, Hans Helge Bartsch<sup>29</sup>, Rüdiger Schul-Wendtland<sup>30</sup>, Markus Hahn<sup>22</sup>, Volker Hanf<sup>31</sup>, Markus Müller-Schimpfle<sup>32</sup>, Ulla Henscher<sup>33</sup>, Renza Roncarati<sup>34</sup>, Alexander Katalinic<sup>35</sup>, Christoph Heitmann<sup>36</sup>, Christoph Honegger<sup>37</sup>, Kerstin Paradies<sup>38</sup>, Vesna Bjelic-Radicic<sup>39</sup>, Friedrich Degenhardt<sup>40</sup>, Frederik Wenz<sup>41</sup>, Oliver Rick<sup>42</sup>, Dieter Hölzel<sup>11</sup>, Matthias Zaiss<sup>43</sup>, Gudrun Kemper<sup>44</sup>, Volker Budach<sup>45</sup>, Carsten Denkert<sup>46</sup>, Bernd Gerber<sup>47</sup>, Hans Tesch<sup>48</sup>, Susanne Hirsmüller<sup>49</sup>, Hans-Peter Sinn<sup>50</sup>, Jürgen Dunst<sup>51</sup>, Karsten Münstedt<sup>52</sup>, Ulrich Bick<sup>53</sup>, Eva Fallenberg<sup>53</sup>, Reina Tholen<sup>54</sup>, Roswita Hung<sup>55</sup>, Freerk Baumann<sup>56</sup>, Matthias W. Beckmann<sup>57</sup>, Jens Blohmer<sup>58</sup>, Peter A. Fasching<sup>57</sup>, Michael P. Lux<sup>57</sup>, Nadia Harbeck<sup>59</sup>, Peyman Hadji<sup>60</sup>, Hans Hauner<sup>61</sup>, Sylvia Heywang-Köbrunner<sup>62</sup>, Jens Huober<sup>6</sup>, Jutta Hübner<sup>63</sup>, Christian Jackisch<sup>64</sup>, Sibylle Loibl<sup>65</sup>, Hans-Jürgen Lück<sup>66</sup>, Gunter von Minckwitz<sup>65</sup>, Volker Möbus<sup>67</sup>, Volkmar Müller<sup>68</sup>, Ute Nöthlings<sup>69</sup>, Marcus Schmidt<sup>70</sup>, Rita Schmutzler<sup>71</sup>, Andreas Schneeweiss<sup>72</sup>, Florian Schütz<sup>72</sup>, Elmar Stickeler<sup>73</sup>, Christoph Thomssen<sup>74</sup>, Michael Untch<sup>75</sup>, Simone Wesselmann<sup>76</sup>, Arno Bücker<sup>77</sup>, Mathias Krockenberger<sup>1</sup>

### Affiliations

- |  |   |
|--|---|
| 1 Universitätsfrauenklinik Würzburg, Universität Würzburg, Würzburg, Germany                           | 10 Praxis für Hämatologie und Onkologie, Kaiserslautern, Germany  |
| 2 Institut für Klinische Epidemiologie und Biometrie (IKE-B), Universität Würzburg, Würzburg, Germany  | 11 Tumorregister München, Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München, München, Germany |
| 3 AWMF-Institut für Medizinisches Wissensmanagement, Marburg, Germany                                  | 12 Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany   |
| 4 Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany | 13 Stiftungsprofessur Selbsthilfeforschung, Tumorzentrum/CCC Freiburg, Universitätsklinikum Freiburg, Freiburg, Germany   |
| 5 Office des Leitlinienprogrammes Onkologie, Berlin, Germany   | 14 Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany   |
| 6 Universitätsfrauenklinik Ulm, Ulm, Germany   | 15 Martin-Luther-Universität Halle-Wittenberg, Halle, Germany   |
| 7 Frauenklinik, Klinikum Esslingen, Esslingen, Germany   |   |
| 8 Frauenklinik, Klinikum St. Marien Amberg, Amberg, Germany  |   |
| 9 Diagnostische Radiologie, Hamburg-Eimsbüttel, Germany  |   |

- 16 Klinik für Strahlentherapie und Radioonkologie, Vivantes Klinikum, Neukölln Berlin, Germany
- 17 Berufsverband der Frauenärzte, Steinbach, Germany
- 18 BRCA-Netzwerk, Bonn, Germany
- 19 Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Germany
- 20 Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
- 21 AGAPLESION Bethesda Klinik, Geriatrie der Universität Ulm, Ulm, Germany
- 22 Universitätsfrauenklinik Tübingen, Tübingen, Germany
- 23 Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Campus Benjamin Franklin, Universitätsklinikum Charité, Berlin, Germany
- 24 Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- 25 III. Medizinische Klinik und Poliklinik, uct, Interdisziplinäre Abteilung für Palliativmedizin, Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Germany
- 26 Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- 27 Brustzentrum, Martin-Luther-Krankenhaus, Berlin, Germany
- 28 Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- 29 Klinik für Tumorbiologie an der Universität Freiburg, Freiburg, Germany
- 30 Radiologisches Institut, Universitätsklinikum Erlangen, Erlangen, Germany
- 31 Frauenklinik Nathanstift, Klinikum Fürth, Fürth, Germany
- 32 Klinik für Radiologie und Nuklearmedizin, Klinikum Frankfurt Höchst, Frankfurt, Germany
- 33 Physiotherapie, Hannover, Germany
- 34 Frauenselbsthilfe nach Krebs – Bundesverband e. V., Bonn, Germany
- 35 Institut für Sozialmedizin und Epidemiologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
- 36 Ästhetisch plastische und rekonstruktive Chirurgie, Camparihaus München, München, Germany
- 37 Gynäkologie und Geburtshilfe, Zuger Kantonsspital, Baar, Switzerland
- 38 Konferenz Onkologischer Kranken- und Kinderkrankenpflege, Hamburg, Germany
- 39 Universitätsfrauenklinik, Abteilung für Gynäkologie, Medizinische Universität Graz, Graz, Austria
- 40 Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, Hannover, Germany
- 41 Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mannheim, Mannheim, Germany
- 42 Klinik Reinhardshöhe Bad Wildungen, Bad Wildungen, Germany
- 43 Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Germany
- 44 Arbeitskreis Frauengesundheit, Berlin, Germany
- 45 Klinik für Radioonkologie und Strahlentherapie, Charité – Universitätsmedizin Berlin, Berlin, Germany
- 46 Institut für Pathologie, Charité – Universitätsmedizin Berlin, Berlin, Germany
- 47 Universitätsfrauenklinik am Klinikum Südstadt, Rostock, Germany
- 48 Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany
- 49 Hospiz am Evangelischen Krankenhaus Düsseldorf, Düsseldorf, Germany
- 50 Pathologisches Institut, Universität Heidelberg, Heidelberg, Germany
- 51 Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
- 52 Frauenklinik Offenburg, Ortenau Klinikum Offenburg-Gengenbach, Offenburg, Germany
- 53 Klinik für Radiologie, Charité – Universitätsmedizin Berlin, Berlin, Germany
- 54 Deutscher Verband für Physiotherapie, Referat Bildung und Wissenschaft, Köln, Germany
- 55 Frauenselbsthilfe nach Krebs, Wolfsburg, Germany
- 56 Centrum für Integrierte Onkologie Köln, Uniklinik Köln, Köln, Germany
- 57 Frauenklinik, Universitätsklinikum Erlangen, CCC Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 58 Klinik für Gynäkologie incl. Brustzentrum, Charité – Universitätsmedizin Berlin, Berlin, Germany
- 59 Brustzentrum, Frauenklinik, Universität München (LMU), München, Germany
- 60 Klinik für Gynäkologie und Geburtshilfe, Krankenhaus Nordwest, Frankfurt, Germany
- 61 Lehrstuhl für Ernährungsmedizin, Klinikum rechts der Isar, Technische Universität München, München, Germany
- 62 Referenzzentrum Mammographie München, München, Germany
- 63 Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
- 64 Klinik für Gynäkologie und Geburtshilfe, Sana Klinikum Offenbach, Offenbach, Germany
- 65 German Breast Group, Neu-Isenburg, Germany
- 66 Gynäkologisch-onkologische Praxis, Hannover, Germany
- 67 Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt Höchst, Frankfurt, Germany
- 68 Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- 69 Institut für Ernährungs- und Lebensmittelwissenschaften, Rheinische Friedrich-Wilhelms Universität Bonn, Bonn, Germany
- 70 Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
- 71 Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany
- 72 Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Germany
- 73 Klinik für Gynäkologie und Geburtsmedizin, Uniklinik RWTH Aachen, Aachen, Germany

74 Universitätsfrauenklinik Halle (Saale), Halle (Saale), Germany  
75 Klinik für Geburtshilfe und Gynäkologie, Helios Klinikum Berlin-Buch, Berlin, Germany  
76 Deutsche Krebsgesellschaft, Berlin, Germany  
77 Klinik für Diagnostische und Interventionelle Radiologie am UKS, Universität des Saarlandes, Homburg, Germany

#### Key words

breast cancer, guideline, screening, diagnosis, follow-up

#### Schlüsselwörter

Mammakarzinom, Richtlinie, Früherkennung, Diagnostik, Nachsorge

received 19.6.2018

accepted 20.6.2018

#### Bibliography

DOI <https://doi.org/10.1055/a-0646-4522>

Geburtsh Frauenheilk 2018; 78: 927–948 © Georg Thieme Verlag KG Stuttgart · New York | ISSN 0016-5751

#### Correspondence

Prof. Dr. med. Achim Wöckel

Frauenklinik und Poliklinik, Universitätsklinikum Würzburg  
Josef-Schneider-Straße 4, 97080 Würzburg  
woeckel\_a@ukw.de



Deutsche Version unter:

<https://doi.org/10.1055/a-0646-4522>

#### ABSTRACT

**Purpose** The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer.

**Methods** The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups

took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure.

**Recommendations** Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease.

#### ZUSAMMENFASSUNG

**Ziele** Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.

**Methoden** Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quelleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.

**Empfehlungen** Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.

## I Guideline Information

### Guidelines program of the DGGG, OEGGG and SGGG

Information on the guidelines program is available at the end of the guideline.

### Citation format

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/0450L, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtsh Frauenheilk 2018; 78: 927–948

## Guideline documents

The complete long version, a short version, and a summary of the conflicts of interest of all the authors are available in German on the AWMF homepage under:

<http://www.awmf.org/leitlinien/detail/ll/032-045OL.html> or [www.leitlinienprogramm-onkologie.de](http://www.leitlinienprogramm-onkologie.de)

## Guideline authors

The German Society for Gynecology and Obstetrics (DGGG) was the lead professional organization behind this guideline together with the German Cancer Society (DKG). The updated guideline presented here was supported by German Cancer Aid as part of their oncology guidelines program (OL program). The working groups consisted of members of the guideline steering group (► **Table 1**), specialists appointed by the participating professional societies and organizations (► **Table 2**), and specialists invited by the steering committee (► **Table 3**); they are the authors of this guideline. Only the mandate holders appointed by the participating professional societies and organizations were eligible to vote on a chapter-by-chapter basis during the voting process (consensus process) after they had disclosed and excluded any conflicts of interest. The guideline was compiled with the direct participation of four patient representatives.

► **Table 1** Steering committee.

	Name	City
1	Prof. Dr. Ute-Susann Albert	Marburg
2	Prof. Dr. Wilfried Budach	Düsseldorf
3	Dr. Markus Follmann, MPH, M. Sc.	Berlin
4	Prof. Dr. Wolfgang Janni	Ulm
5	Prof. Dr. Ina Kopp	Marburg
6	Prof. Dr. Rolf Kreienberg	Landshut
7	PD Dr. Mathias Krockenberger	Würzburg
8	Prof. Dr. Thorsten Kühn	Esslingen
9	Dipl.-Soz. Wiss. Thomas Langer	Berlin
10	Dr. Monika Nothacker	Marburg
11	Prof. Dr. Anton Scharl	Amberg
12	Prof. Dr. Ingrid Schreer	Hamburg-Eimsbüttel
13	Prof. Dr. Achim Wöckel (Leitlinienkoordination)	Würzburg

Methodological advice: Prof. Dr. P. U. Heuschmann, University of Würzburg

► **Table 2** Participating professional societies and organizations.

Professional societies	1st mandate holder	2nd mandate holder (deputy)
Radiological Oncology Working Group [AG Radiologische Onkologie (ARO)]	Prof. Dr. Wilfried Budach, Düsseldorf	Prof. Dr. Frederik Wenz, Mannheim
Supportive Measures in Oncology, Rehabilitation and Social Medicine Working Group [AG Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin (ASORS)]	Prof. Dr. Hartmut Link, Kaiserslautern	Prof. Dr. Oliver Rick, Bad Wildungen
Association of German Tumor Centers [Arbeitsgemeinschaft Deutscher Tumorzentren e. V. (ADT)]	Prof. Dr. Jutta Engel, Munich	Prof. Dr. Dieter Hölzel, Munich
German Society of Gynecological Oncology [Arbeitsgemeinschaft für gynäkologische Onkologie (AGO)]	Prof. Dr. Tanja Fehm, Düsseldorf	Prof. Dr. Anton Scharl, Amberg
Prevention and Integrative Oncology Working Group [AG Prävention und Integrative Onkologie (PRIO)]	Prof. Dr. Volker Hanf, Fürth	Prof. Dr. Karsten Münstedt, Offenburg
Psycho-oncology Working Group of the German Cancer Society [Arbeitsgemeinschaft für Psychoonkologie in der Deutschen Krebsgesellschaft e. V. (PSO)]	Prof. Dr. Joachim Weis, Freiburg	
Internal Oncology Working Group [Arbeitsgemeinschaft Internistische Onkologie (AIO)]	Dr. Anja Welt, Essen	Dr. Matthias Zaiss, Freiburg
Women's Health Work Group [Arbeitskreis Frauengesundheit (AKF)]	Prof. Dr. Anke Steckelberg, Halle	Gudrun Kemper, Berlin
Professional Association of German Radiation Therapists [Berufsverband Deutscher Strahlentherapeuten e. V. (BVDST)]	Prof. Dr. Petra Feyer, Berlin	Prof. Dr. Volker Budach, Berlin
Professional Association of German Gynecologists [Berufsverband für Frauenärzte e. V.]	Dr. Klaus König, Steinbach	
BRCA Network [BRCA-Netzwerk e. V.]	Andrea Hahne, Bonn	Traudl Baumgartner, Bonn
German Society for Pathology [Deutsche Gesellschaft für Pathologie]	Prof. Dr. Hans H. Kreipe, Hanover	Prof. Dr. Carsten Denkert, Berlin

Continued next page

► **Table 2** Participating professional societies and organizations. (Continued)

Professional societies	1st mandate holder	2nd mandate holder (deputy)
Surgical Oncology Working Group [Chirurgische AG für Onkologie (CAO-V)]	Prof. Dr. Wolfram Trudo Knoefel, Düsseldorf	
German Society of Geriatrics [Deutsche Gesellschaft für Geriatrie (DGG)]	Prof. Dr. Michael Denking, Ulm	
German Society of Gynecology and Obstetrics [Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG)]	Prof. Dr. Sara Brucker, Tübingen	Prof. Dr. Bernd Gerber, Rostock
German Society of Hematology and Oncology [Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)]	Prof. Dr. Diana Lüftner, Berlin	Prof. Dr. Hans Tesch, Frankfurt
German Society of Human Genetics [Deutsche Gesellschaft für Humangenetik e. V. (GfH)]	Prof. Dr. Christian Kubisch, Hamburg	
German Society for Palliative Medicine [Deutsche Gesellschaft für Palliativmedizin (DGP)]	Dr. Christina Gerlach, M. Sc., Mainz	Dr. Susanne Hirschmüller, M. Sc., Düsseldorf
Professional Association of German Pathologists [Bundesverband Deutscher Pathologen e. V.]	Prof. Dr. Annette Lebeau, Hamburg	Prof. Dr. Hans-Peter Sinn, Heidelberg
German Society of Psychosomatic Obstetrics and Gynecology [Deutsche Gesellschaft für psychosomatische Frauenheilkunde und Geburtshilfe (DGPF)]	PD Dr. Friederike Siedentopf, Berlin	
German Society for Radiation Oncology [Deutsche Gesellschaft für Radioonkologie (DEGRO)]	Prof. Dr. Cordula Petersen, Hamburg	Prof. Dr. Jürgen Dunst, Kiel
German Society for Rehabilitation Sciences [Deutsche Gesellschaft für Rehabilitationswissenschaften (DGRW)]	Prof. Dr. Hans Helge Bartsch, Freiburg	
German Society for Senology [Deutsche Gesellschaft für Senologie (DGS)]	Prof. Dr. Rüdiger Schulz-Wendtland, Erlangen	
German Society for Ultrasound in Medicine [Deutsche Gesellschaft für Ultraschall in der Medizin e. V. (DEGUM)]	Prof. Dr. Markus Hahn, Tübingen	
German Roentgen Society [Deutsche Röntgengesellschaft e. V.]	Prof. Dr. Markus Müller-Schimpfle, Frankfurt	Till 31.12.16: Prof. Dr. Ulrich Bick, Berlin From 01.01.17: PD Dr. E. Fallenberg, Berlin
German Physiotherapy Society [Deutscher Verband für Physiotherapie e. V. (ZVK)]	Ulla Henscher, Hanover	Reina Tholen, Köln
Self-help group for women after cancer [Frauenselbsthilfe nach Krebs]	Dr. Renza Roncarati, Bonn	Roswita Hung, Wolfsburg
Association of Epidemiological Cancer Registries in Germany [Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (GEKID)]	Prof. Dr. Alexander Katalinic, Lübeck	
German Society of Plastic, Reconstructive and Aesthetic Surgery [Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgie (DGPRÄC)]	Prof. Dr. Christoph Heitmann, Munich	
Swiss Society of Gynecology and Obstetrics [Gynécologie Suisse (SGGG)]	Dr. Christoph Honegger, Baar	
Conference of Oncological Nursing and Pediatric Nursing [Konferenz Onkologischer Kranken- und Kinderkrankenpflege (KOK)]	Kerstin Paradies, Hamburg	
Austrian Society of Gynecology and Obstetrics [Österreichische Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG)]	Prof. Dr. Vesna Bjelic-Radasic, Graz	
Ultrasound Diagnosis in Gynecology and Obstetrics [Ultraschalldiagnostik in Gynäkologie und Geburtshilfe (ARGUS)]	Prof. Dr. med. Dr. h. c. Friedrich Degenhardt, Hanover	

► **Table 3** Experts contributing in an advisory capacity and other contributors.

Name	City
<b>Experts contributing in an advisory capacity</b>	
PD Dr. Freerk Baumann	Cologne
Prof. Dr. Matthias W. Beckmann	Erlangen
Prof. Dr. Jens Blohmer	Berlin
Prof. Dr. Arno Bücker	Homburg
Prof. Dr. Peter A. Fasching	Erlangen
Prof. Dr. Nadia Harbeck	Munich
Prof. Dr. Peyman Hadji	Frankfurt
Prof. Dr. Hans Hauner	Munich
Prof. Dr. Sylvia Heywang-Köbrunner	Munich
Prof. Dr. Jens Huober	Ulm
Prof. Dr. Jutta Hübner	Jena
Prof. Dr. Christian Jackisch	Offenbach
Prof. Dr. Sibylle Loibl	Neu-Isenburg
Prof. Dr. Hans-Jürgen Lück	Hanover
Prof. Dr. Michael P. Lux	Erlangen
Prof. Dr. Gunter von Minckwitz	Neu-Isenburg
Prof. Dr. Volker Möbus	Frankfurt
Prof. Dr. Volkmar Müller	Hamburg
Prof. Dr. Ute Nöthlings	Bonn
Prof. Dr. Marcus Schmidt	Mainz
Prof. Dr. Rita Schmutzler	Cologne
Prof. Dr. Andreas Schneeweiss	Heidelberg
Prof. Dr. Florian Schütz	Heidelberg
Prof. Dr. Elmar Stickeler	Aachen
Prof. Dr. Christoph Thomssen	Halle (Saale)
Prof. Dr. Michael Untch	Berlin
Dr. Simone Wesselmann, MBA	Berlin
Dr. Barbara Zimmer, MPH, MA (Oncology Competence Center, MDK [Medical Service of the Health Insurance Funds] North-Rhine, not listed as an author at the explicit request of the MDK)	Düsseldorf
<b>Other contributors</b>	
Katharina Brust, B.Sc. (guideline secretariat)	Würzburg
Dr. Jasmin Festl (guideline assessment, selection of relevant publications)	Würzburg
Steffi Hillmann, MPH (search and assessment of guidelines)	Würzburg
PD Dr. Mathias Krockenberger (selection of relevant publications)	Würzburg
Stephanie Stangl, MPH	Würzburg
Dr. Tanja Stüber (selection of relevant publications)	Würzburg

## Abbreviations of the S3 Breast Cancer Guideline

ADH	atypical (intra) ductal hyperplasia
AI	aromatase inhibitor
AML	acute myeloid leukemia
APBI	accelerated partial breast irradiation
ASCO	American Society of Clinical Oncology
ADL	activities of daily living
AUC	area under the curve
BÄK	German Medical Association (Bundesärztekammer)
BCT	breast-conserving therapy
BI-RADS	breast imaging reporting and data system
BMI	body mass index
BPM	bilateral prophylactic mastectomy
BPSO	bilateral prophylactic salpingo-oophorectomy
BRCA1/2	breast cancer-associated gene 1/2
CAM	complementary and alternative methods
CAP	College of American Pathologists
CD	cognitive dysfunction
CDLT	complex/complete decongestive lymphatic therapy
CGA	comprehensive geriatric assessment
CHF	chronic heart failure
CIPN	chemotherapy-induced peripheral neuropathy
CISH	chromogenic in situ hybridization
CM	contrast media
CNB	core needle biopsy
CNS	central nervous system
CT	computed tomography
DCIS	ductal carcinoma in situ
DBT	digital breast tomosynthesis
DFS	disease-free survival
DGS	German Society for Senology (Deutsche Gesellschaft für Senologie)
DKG	German Cancer Society (Deutsche Krebsgesellschaft)
EC	expert consensus
ECE	extracapsular tumor extension
EIC	extensive intraductal component
ER	estrogen receptor
ESA	erythropoiesis-stimulating agents
ESAS	Edmonton Symptom Assessment Scale
ET	estrogen therapy
FEA	flat epithelial atypia
FISH	fluorescent in situ hybridization
FN	febrile neutropenia
FNA	fine needle aspiration
FNB	fine needle biopsy
G-CSF	granulocyte colony-stimulating factor
GnRH <sub>a</sub>	gonadotropin-releasing hormone agonist
HADS	Hospital Anxiety and Depression Scale
HER2	human epidermal growth factor receptor 2
HT	hormone therapy
IARC	International Agency for Research on Cancer
IBC	inflammatory breast cancer
IHC	immunohistochemistry
IMRT	intensity-modulated radiotherapy
IORT	intraoperative radiation therapy

IQWiG	Institute for Quality and Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen)
ISH	in situ hybridization
ITC	intrathecal chemotherapy
LABC	locally advanced breast cancer
LCIS	lobular carcinoma in situ
LN	lymph node
GL	guideline
LoE	level of evidence
LVEF	left ventricular ejection fraction
LVI	lymphatic vessel invasion
Lsp	lumbar spine
MDS	myelodysplastic syndrome
MG	mammography
MRI	magnetic resonance imaging
MSP	mammography screening program
NAC	nipple-areolar complex
NACT	neoadjuvant chemotherapy
NCCN	National Comprehensive Cancer Network
NICE	National Institute for Health and Clinical Excellence
NNT	number needed to treat
NZGG	New Zealand Guidelines Group
OP	operation
OS	overall survival
PBI	partial breast irradiation
pCR	pathological complete remission
PET	positron emission tomography
PFS	progression-free survival
PI	proliferation index
PMRT	postoperative radiotherapy
PNP	polyneuropathy
POS	Palliative Outcome Scale
PR	progesterone receptor
PST	primary systemic therapy
QoL	quality of life
RCT	randomized controlled trial
RFA	radiofrequency ablation
ROR	risk of recurrence
RR	relative risk
RS	recurrence score
SABCS	San Antonio Breast Cancer Symposium
SBRT	stereotactic radiotherapy
SGB	German Social Security Code (Sozialgesetzbuch)
SIB	simultaneous integrated boost
SIGN	Scottish Intercollegiate Guidelines Network
SISH	silver-enhanced in situ hybridization
SLN	sentinel lymph node
SLNB	sentinel lymph node biopsy
SSM	skin-sparing mastectomy
TACE	transarterial chemoembolization
TILs	tumor-infiltrating lymphocytes
TNBC	triple-negative breast cancer
TNM classification	tumor-node-metastasis classification
UICC	Union for International Cancer Control
US	ultrasound

VMAT	volumetric arc therapy
WHO	World Health Organization

## II Guideline Application

### Purpose and objectives

The most important reason to update the interdisciplinary guideline was the epidemiological impact of breast cancer and its related burden of disease, which are still high. This is the context in which the impact of new management concepts and their implementation needed to be evaluated.

### Targeted areas of patient care

The guideline covers outpatient care, inpatient care and rehabilitative care.

### Target patient groups

The recommendations of the guideline are aimed at all women and men who develop breast cancer as well as their relatives.

### Target user groups/Target audience

The recommendations of the guideline are addressed to all physicians and professionals who provide screening services to women or care to patients with breast cancer (gynecologists, general practitioners, human geneticists, radiologists, pathologists, radio-oncologists, hemato-oncologists, psycho-oncologists, physiotherapists, nursing staff, etc.).

### Adoption of the guideline and period of validity

This guideline is valid from December 1, 2017 through to November 30, 2022. Because of the contents of this guideline, this period of validity is only an estimate. It may be necessary to update the guideline because of new scientific evidence and knowledge as well as new developments in the methodology used for these guidelines. Moreover, it may be necessary to edit and revise the guideline's contents and to re-evaluate and revise the key statements and recommendations of the guidelines at regular intervals.

## III Methodology

### Basic principles

The method used to prepare this guideline was determined by the class to which this guideline is assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and regulations for the different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest class (S3). The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was subdivided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest class (S3) combines both approaches. This guideline is classified as: S3.

## Grading of evidence

This guideline used the 2009 version of the system of the Oxford Centre for Evidence-based Medicine (levels 1–5) to classify the risk of bias in identified studies. This system classifies studies according to various clinical questions (benefit of therapy, prognostic value, diagnostic validity). For more detailed information, abbreviations and notes, see: <http://www.cebm.net/?o=1025>.

## Grading of recommendations

While the classification of the quality of the evidence (strength of evidence) serves as an indication of the robustness of the published data and therefore expresses the extent of certainty/uncertainty about the data, the classification of the level of recommendation reflects the results of weighing up the desirable and adverse consequences of alternative approaches. This guideline shows the level of the evidence for the underlying studies as well as the strength of the recommendation (level of recommendation) for all evidence-based Statements and Recommendations. This guideline differentiates between three levels of recommendation (► **Table 4**). The levels reflect the strength of the respective recommendation and are also mirrored in the terms used when formulating the recommendation.

► **Table 4** Grading of recommendations.

Level of recommendation	Description	Terms used
A	strong recommendation, highly binding	must
B	recommendation, moderately binding	should
0	open recommendation, not binding	may

## Statements

Statements are expositions or explanations of specific facts, circumstances or problems with no direct recommendations for action. Statements are adopted after a formal consensus process using the same approach as that used when formulating recommendations and can be based either on trial results or expert opinions.

## Expert consensus

As the expression implies, this term refers to consensus decisions taken specifically with regard to Recommendations/Statements

without a previous systematic search of the literature (S2k) or when evidence is lacking (S2e/S3). The term “Expert Consensus” (EC) used here is synonymous with terms such as “Good Clinical Practice” (GCP) or “Clinical Consensus Point” used in other guidelines. The level of recommendation is graded as previously described in the Chapter “Grading of recommendations”, but the grading is only presented semantically (“must”/“must not” or “should”/“should not” or “may”/“may not”) without the use of symbols.

## Guideline report

To edit and update the various topic areas, an adaptation of existing guidelines was planned for around 80% of Statements and Recommendations in accordance with the AWMF Guidance Manual. To do this, a systematic search was carried out for source guidelines developed specifically for women with breast cancer and published after 2013. Findings were compared with the IQWiG guideline report No. 224 (Systematische Leitlinienrecherche – und Bewertung sowie Extraktion relevanter Recommendations für das DMP Brustkrebs [Systematic guideline search and appraisal as well as extraction of relevant recommendations for a DMP for breast cancer]). A further inclusion criterion was compliance with methodological standards. Guidelines were included if they complied with at least 50% of Domain 3 (Rigour of Development) of the AGREE II instrument. A corresponding search and evidence assessment was specified in accordance with AWMF guidelines (systematic search, selection, compilation of evidence tables) for those recommendations which could not be adapted or had to be newly created. For Recommendations and Statements which had to be newly developed, the formulation of corresponding key questions and the systematic search were done based on aggregated sources of evidence (meta-analyses, systematic reviews, etc.), in specific cases also on individual publications. The appropriate list of titles and abstracts up until the identification of the full text were selected by two independent raters. After the search and selection processes were completed, the necessary evidence tables which formed the basis for the consensus conferences were compiled by the Methods group (financial support was provided and allowed a researcher to be specifically hired for this purpose). The classification system of the Oxford Centre for Evidence-based Medicine (version 2009) was used to grade the evidence. To update this guideline, Recommendations and Statements were adopted and levels of recommendation (► **Table 4**) was determined during two structured consensus conferences which were preceded by a preliminary online ballot.

The guideline report provides an overview of the search strategies and selection processes used to select the literature and to formulate and grade the recommendations.



## IV Guideline

### 1 Early detection, mammography screening

No.	Recommendations/Statements	EG	LoE	Sources
3.8.	a) The most important population-related risk factor for developing breast cancer in both women and men is advancing age.	A	2a	[1–3]
	b) It is very rare for men to develop breast cancer. Special breast cancer imaging and screening methods must not be recommended to asymptomatic men. A diagnosis is made after the patient presents with clinical symptoms which are then investigated using mammography and ultrasound. The clinical workup must be carried out in accordance with the recommendations for women. (See Chapter: Breast Cancer in Men.)	EC		
3.9.	<p>a) Early detection of breast cancer is an interdisciplinary task. It requires a quality-assured interdisciplinary combination of clinical examinations, instrument-based diagnostic procedures, histological evaluations and pathomorphological evaluations.</p> <p>b) The chain of care requires complex, quality-assured medical documentation to be able to bring together and coordinate all aspects of quality management.</p> <p>c) Every cancer screening program must be continually evaluated with regard to relevant outcomes (e.g., incidence, mortality, morbidity and patient-related outcomes) and risks (e.g., false-positive and false-negative findings, over-diagnosis). The process data of the screening programs and the breast centers and the data from the population-related cancer registries of the various German federal states are used for this after the respective data have been compared and adjusted. If possible, cancer registries must continuously provide differentiated data for their respective federal state and screening units from the start of the national screening program for Germany in 2005. Patient lists (e.g., about interval cancers, contralateral findings or local recurrences) form part of the continuous re-evaluation of data. It is important to ensure that data evaluation is completely independent.</p> <p>d) To ensure that patients receive the best possible treatment, further therapy to treat breast cancers detected during screening must be carried out in certified breast centers. Good communication between the screening center and certified breast center with careful data collection and registration is needed to ensure a high quality of care.</p>	EC		

#### 1.1 Participatory decision-making

No.	Recommendations/Statements	EG	LoE	Sources
3.10.	<p>a) Screening for the detection of breast cancer may be associated with physical and psychological stress. It is important to take account of this by offering detailed information and using an effective communication strategy.</p> <p>b) The information given to patients during breast cancer screening must not just consist of pre-formulated texts and statements; patients also require medical counselling which takes account of the patient's preferences, worries and fears and permits a form of participatory decision-making. For mammography screening the information provided to patients must be provided primarily in writing; on the invitation letter for screening, patients must additionally be informed that they have the option to request a consultation with a doctor.</p>	EC		

#### 1.2 Mammography screening

No.	Recommendations/Statements	EG	LoE	Sources
3.11.	a) Mammography is the only method associated with a verified reduction in breast cancer mortality rates.	ST	1a	[1–9]
	b) It is recommended that women between the ages of 50 and 69 participate in the (German) national mammography screening program. Women aged 70 and above should be offered screening which takes account of their individual risk profile and health status as well as whether they have a life expectancy of more than 10 years.	A/B	1a	[1, 2, 7, 9–13]
	c) The reduction of breast cancer mortality has also been proven for women between the ages of 40 and 49 years and outweighs any risks arising from exposure to radiation. The reduction in mortality is, however, lower than that reported for women between the ages of 50 and 69 years and, in relative terms, there are more false-positive and false-negative findings in the younger group. The decision to have screening or not should therefore be based on an individual risk analysis, the weighing up of benefits and risk and should take the woman's preferences and objections into account.	B	1b	[1, 2, 8, 14]
	d) The quality of the structures, processes and results for curative mammography must be the equivalent of those described above.	EC		
	e) If the mammography findings are category 0, III, IV or V (unclear or suspicious findings), additional workup procedures should be carried out within one week to minimize the psychological stress for the affected woman.	EC		

### 1.3 Breast cancer screening methods

No.	Recommendations/Statements	EG	LoE	Sources
3.12.	a) As part of the statutory screening for breast cancer, women must be offered medical counselling which provides them with information about potential risk factors and reviews their medical history and familial risks.	EC		
	b) Breast self-exams are not adequate to reduce breast cancer mortality if they are the only method used for screening, even if women carry out their breast exams regularly and have received training to perform the exam properly.	ST	1a	[1, 2]
	c) Women should receive qualified information which will encourage them to familiarize themselves with normal changes of their own bodies. These include the appearance of the breast and how it should feel. This should help women notice any changes themselves.	EC		
	d) Clinical breast examinations (i.e., the inspection and palpation of the breast and the assessment of lymph drainage) should be offered to women from the age of 30 years as part of statutory breast cancer screening. Clinical examination of the breast and axilla is not recommended as the only method of breast cancer screening.	EC		
	e) The systematic use of ultrasound is not recommended as the only method of breast cancer screening.	EC		

#### Sonography

There are no studies on the use of sonography instead of mammography as the only method for breast cancer screening (For details, see the long version of this guideline [available in German]).

### 1.4 Additional diagnostic imaging procedures to screen breasts with high mammographic density

No.	Recommendations/Statements	EG	LoE	Sources
3.13.	a) Increased mammographic density is an independent moderate risk factor for breast cancer. Mammographic density and mammography sensitivity are negatively correlated.	B	3a	[1, 15–17]
	b) Evidence on the use of additional imaging procedures is limited. With the exception of high-risk situations, ultrasound currently appears to be a suitable method to supplement mammography. Sonography can increase density-related sensitivity; however, there is no evidence that it reduces mortality. Sonography used for screening purposes is associated with a higher rate of biopsies than the (German) national mammography screening program.	B	3a	[1, 8, 9, 18–21]
	c) Tomosynthesis can increase sensitivity. Trialing tomosynthesis in a quality-assured program should be considered.	B/0	1b	[22–24]

### 1.5 Women with increased risk of breast cancer, hereditary breast cancer

Around 30% of all women with breast cancer in Germany have a familial risk of breast cancer and meet the inclusion criteria for genetic testing which were established and validated by the German Consortium for Hereditary Breast and Ovarian Cancer (see Statement 3.14) [25]. These are based on a mutation detection rate of at least 10% [26].

No.	Recommendations/Statements	EG	LoE	Sources
3.14.	Genetic testing should be offered if women have a familial or individual risk with an at least 10% probability of mutation. This applies if, in one line of the family, <ul style="list-style-type: none"> <li>▪ at least 3 women developed breast cancer</li> <li>▪ at least 2 women developed breast cancer, one of whom was aged less than 51 years</li> <li>▪ at least 1 woman developed breast cancer and 1 woman developed ovarian cancer</li> <li>▪ at least 2 women developed ovarian cancer</li> <li>▪ at least 1 woman developed breast cancer and ovarian cancer</li> <li>▪ at least 1 woman aged 35 years or younger developed breast cancer</li> <li>▪ at least 1 woman aged 50 years or less developed bilateral breast cancer</li> <li>▪ at least 1 man developed breast cancer and 1 woman developed breast cancer or ovarian cancer.</li> </ul> Patients should be given a suitable period for reflection before carrying out diagnostic procedures.	B		[27]
		EC/2a for the probability of a mutation		

*Continued next page*

No.	Recommendations/Statements	EG	LoE	Sources
3.15.	<p>The consultation must permit participatory decision-making. To ensure they can adequately participate in decision-making, women must receive extensive and detailed information and their preferences must be identified and taken into account in the decision-making process. Evidence-based support can improve the decisions taken by affected women.</p> <p>The following topics must be included in the risk consultation prior to genetic testing:</p> <ul style="list-style-type: none"> <li>the probability of a mutation</li> <li>the risk of developing disease if findings are positive</li> <li>the benefit and harm of preventive and therapeutic options including the option to not do anything</li> <li>the probability of false-negative findings</li> <li>the importance of genetic testing for other family members</li> </ul> <p>After obtaining genetic findings, the patient's understanding of the following topics must be expanded during the risk consultation before she is offered preventive measures:</p> <ul style="list-style-type: none"> <li>the risk of developing disease depends on the genetic findings, age and co-morbidities (natural course)</li> <li>the probability of false-positive and false-negative test results with intensified screening</li> <li>the benefit of preventive options (intensified screening, prophylactic surgery, drug therapies) for reducing mortality and morbidity and improving quality of life</li> <li>the risks of preventive options, including long-term sequelae</li> <li>the concurrent risks, prognosis and treatability in the event that the patient develops disease without undertaking preventive measures, based on the specific manifestation of the genetically defined tumor subtype</li> <li>the possible risk of associated tumors</li> <li>the patient should be offered psycho-oncologic counselling</li> </ul>	EC/1a for improvements in decision-making		[28 – 33]
3.16.	<p>a) BRCA1-associated breast cancers often have a characteristic histopathological and immunohistochemical phenotype:</p> <ul style="list-style-type: none"> <li>invasive carcinoma with medullary features</li> <li>G3 morphology</li> <li>estrogen receptor, progesterone receptor and HER2 negativity (triple negative)</li> </ul> <p>b) If these characteristics are present, the pathologist should inform the patient that they could have a hereditary propensity to disease.</p>	2a for histopathological characteristics		
3.17.	<ul style="list-style-type: none"> <li>Patients with a pathogenic BRCA1/2 mutation (IARC class 4/5) should and patients with a residual lifetime risk of <math>\geq 30\%</math> can undergo intensified screening including MRI only following a transparent quality assurance process and after appropriate evaluation.</li> <li>Additional mammography screening after the age of 40 should be carried out as part of a transparent quality assurance process and after appropriate evaluation.</li> </ul>	EC		
3.18.	<p>a)</p> <ul style="list-style-type: none"> <li>The surgical therapy of BRCA-associated breast cancer corresponds to the guideline recommendations for sporadic breast cancer.</li> <li>Mastectomy offers no survival benefits compared to breast-conserving therapy.</li> <li>The drug therapy used to treat BRCA-associated breast cancer corresponds to the guideline recommendations for sporadic breast cancer.</li> </ul> <p>b) There are some indications that platinum-based chemotherapy can result in a better response to treatment compared to standard chemotherapy.</p>			[34 – 39]
3.19.	<ul style="list-style-type: none"> <li>Healthy women with a BRCA1 or BRCA2 mutation have an increased lifelong risk of developing breast cancer.</li> <li>In healthy women with a pathogenic BRCA1 or BRCA2 gene mutation, bilateral prophylactic mastectomy results in a reduction in the incidence of breast cancer. There is not yet sufficient evidence for a reduction in breast cancer-specific mortality or overall mortality following bilateral prophylactic mastectomy.</li> <li>Every individual decision for or against bilateral prophylactic mastectomy requires in every case that the patient is given detailed information with multidisciplinary counselling about the potential benefits and disadvantages of such a procedure and must include the consideration of potential alternatives.</li> </ul>	2a		[26, 40 – 48]
3.20.	<ul style="list-style-type: none"> <li>Women with a pathogenic BRCA1 or BRCA2 mutation have an increased lifelong risk of ovarian cancer, fallopian tube cancer and/or primary peritoneal cancer.</li> <li>In healthy women with a pathogenic BRCA1 or BRCA2 gene mutation, prophylactic adnexectomy reduces the incidence of ovarian cancer and reduces overall mortality. Prophylactic bilateral salpingo-oophorectomy must therefore be discussed and recommended on a case-by-case basis and as part of extensive multidisciplinary counselling about the potential benefits and disadvantages of such a procedure and must take the lack of effective screening options into account.</li> </ul>	2a		[40, 44, 49 – 52]

Continued next page

No.	Recommendations/Statements	EG	LoE	Sources
3.21.	<ul style="list-style-type: none"> <li>Women with a pathogenic BRCA1 or BRCA2 gene mutation who have already developed breast cancer have an increased risk of developing contralateral breast cancer. The risk also depends on the affected gene and on the age at which the woman first developed disease and must be taken into account during counselling.</li> <li>In women with a pathogenic BRCA1 or BRCA2 gene mutation, contralateral, secondary prophylactic mastectomy reduces the risk of contralateral cancer. When considering whether contralateral secondary prophylactic mastectomy is indicated, the prognosis for the primary tumor must be taken into account.</li> <li>In patients with a pathogenic BRCA1 or BRCA2 gene mutation, prophylactic adnexectomy reduces breast cancer-specific mortality and increases overall survival.</li> </ul>	2a		[27, 53–60]
3.22.	The benefit of prophylactic or secondary prophylactic contralateral mastectomy has not been proven for women with verified BRCA1 or BRCA2 gene mutations.	2a		[55, 61, 62]
3.23.	<p>Healthy women, women who have developed disease, and men with an increased risk of developing disease should be encouraged to contact cancer self-help organizations to obtain further information if required and to encourage them to insist on their right of self-determination.</p> <p>They should be supported:</p> <ul style="list-style-type: none"> <li>if there is a suspicion of hereditary propensity to disease</li> <li>as they consider genetic testing</li> <li>before undertaking prophylactic measures</li> </ul> <p>Appropriate printed information material should be available.</p>	EC		

## 2 Diagnostic Workup of Breast Cancer

No.	Recommendations/Statements	EG	LoE	Sources
4.1.	<p>a) The basic examination consists of:</p> <ul style="list-style-type: none"> <li>taking the patient's history and familial history together with a clinical breast examination consisting of inspection, palpation of the breast and the lymphatic drainage areas</li> <li>mammography</li> <li>ultrasound</li> </ul> <p>If the findings of the clinical breast examination are suspicious, the diagnostic workup must include suitable imaging techniques and, if required, a histological examination.</p>	EC		
	<p>b) The effects of endogenous and exogenous hormones should be taken into account when carrying out diagnostic procedures and evaluating the findings of diagnostic procedures.</p>	B	2b	[63–66]

### 2.1 Imaging methods

No.	Recommendations/Statements	EG	LoE	Sources
4.2.	<p>a) If the findings are suspicious, women aged 40 and above must have a mammography.</p> <p>b) In women younger than 40 years of age, mammography must be used if the suspicion of malignancy based on clinical examination, ultrasound and percutaneous biopsy (when indicated) cannot be ruled out with sufficient certainty.</p> <p>c) Suitable further imaging procedures must be considered in addition to mammography.</p> <p>d) Bilateral mammography must be carried out prior to starting treatment if malignancy is confirmed.</p>	EC		
	<p>e) Ultrasound must be carried out if the mammographic density is high or assessment based on mammography provides only limited results.</p>	A	1b	[19, 20, 67–73]
4.3.	<p>a) Sonography must be used to further evaluate clinically unclear findings and to assess category 0, III, IV and V findings detected with mammography or MRI.</p>			
	<p>b) The goal in standard breast sonography is a systematic and reproducible examination of the breast and axilla. Findings must be reproducibly documented.</p>	EC		
	<p>c) The quality of structures, processes and outcomes should also be verified for breast sonography.</p>	EC		
4.4.	<p>a) In a diagnostic setting, MRI with CM should be limited to those cases where a lesion cannot be adequately identified using conventional diagnostic methods (MG, US) or percutaneous biopsy.</p>	B	2a	[74]
	<p>b) Carrying out MRI with CM prior to treatment to examine an already diagnosed breast cancer is only justified in specific exceptional cases. The decision that MRI with CM is indicated should be made during a multidisciplinary tumor conference.</p>	B	1a	[75–77]
	<p>c) MRI with CM of the breast must only be carried out if an MRI-supported intervention can be carried out in the same center or it is possible to access MRI-supported interventions, and the histological findings of the MRI intervention are presented to an interdisciplinary conference to document the outcome quality.</p>	EC		

## 2.2 Diagnostic confirmation

No.	Recommendations/Statements	EG	LoE	Sources
4.5.	a) The specimens for the histological workup must be obtained by punch biopsy, vacuum biopsy or, in exceptional cases, by open excision biopsy.	A	3a	[73, 78]
	b) Imaging procedures which clearly show the lesion must be used to guide the biopsy. The choice of biopsy method must take the diagnostic certainty and the risk of side effects into account. The investigator must use suitable measures to ensure that the biopsy site can be found again (e.g. clip placement).	EC		
	c) If a sonographic correlate has been identified for a lesion detected primarily using mammography or MRI, sampling must be carried out with ultrasound-guided punch biopsy.	EC		
	d) Stereotactic vacuum biopsy must be used if micro-calcifications are present without accompanying focal findings.	A	2b	[79]
	e) Vacuum biopsy should be used for mammography-guided or MRI-guided tissue biopsy.	EC		
	f) The correlation between the histological findings and the clinically suspicious findings must be reviewed and documented for all biopsies.	EC		
	g) If the histopathological results of a category 4 or 5 lesion on imaging which was representatively sampled are benign, an appropriate control imaging procedure should be carried out after 6 months.	EC		
	h) Punch biopsy should primarily be used for the fine-tissue clarification of lymph nodes classified as suspicious on imaging.	A	2a	[80–83]
	i) After the target tissue has been clearly identified, $\geq 3$ samples should be taken during interventional, preferably ultrasound-guided punch biopsy, using a punch biopsy needle with a diameter of $\leq 14$ G.	B	3b	[84–86]
	j) In vacuum biopsies, $\geq 12$ samples should be taken using a 10-G needle. If other needle diameters (between 8 G and 11 G) are used, the biopsied specimens obtained should result in an equivalent sample volume.	EC		
4.6.	Primary open diagnostic excision biopsy must only be carried out in exceptional cases.	A	3a	[79, 87]
	Pre-operative or intraoperative marking must be carried out using a method which can clearly show the lesion, particularly when investigating non-palpable lesions. Evidence of adequate resection must be provided intraoperatively by specimen radiography or specimen ultrasound. If MRI-guided marking is carried out, then a control MR must be carried out within 6 months if the benign lesion was histologically unspecific.	EC		
	When carrying out preoperative wire marking of a non-palpable finding, the wire must be located in the focal area and extend less than 1 cm beyond this area. If the wire does not penetrate the focal area, the distance between the wire and the edge of the focal area must be $\leq 1$ cm. In patients with extensive focal findings, it may be useful to place several markings around the surgically relevant target volume.	EC		
	The surgically resected material must be clearly topographically marked and sent to the pathologist without incising the sampled tissue material.	EC		
4.7.	Staging (of the lungs, liver, and skeleton) should be carried out in high-risk patients newly diagnosed with UICC stage II (and higher) breast cancer and in patients newly diagnosed with stage III or IV breast cancer without symptoms of metastasis.	B	2a	[88]
	Staging based on imaging must be carried out in patients newly diagnosed with breast cancer and a clinical suspicion of metastasis.	A	2a	[88]
	Full-body staging should only be carried out in women with a high risk of metastasis (N+, >T2) and/or aggressive tumor biology (e.g.: Her2+, triple-negative), clinical signs, symptoms, and if systemic chemotherapy/antibody therapy is planned. Full-body staging should be done using a thoracic-abdominal CT scan and skeletal scintigraphy.	EC		

### 2.3 Diagnosis of local/loco-regional recurrence

No.	Recommendations/ Statements	EG	LoE	Sources
5.1.	Patients should be informed about the clinical signs of recurrence.	B	Adapted from guideline	[89]
5.2.	In asymptomatic patients, no other diagnostic methods should be carried out in addition to the standard methods recommended for follow-up.	B	Adapted from guideline	[89]
5.3.	As with primary breast cancer, imaging to clarify a suspicion of local/loco-regional recurrence must consist of mammography and breast ultrasound. (A) Breast MRI should be used if, after considering the patient's level of risk, it is not possible to make a sufficiently certain diagnosis using other methods. (B)	A/B	Adapted from guideline	[90]
5.4.	Breast ultrasound and minimally invasive biopsy methods are suitable methods for the primary histological clarification of loco-regional recurrence.	B	Adapted from guideline	[73]
5.5.	If there is a suspicion of distant metastasis, suitable diagnostic methods can be used to exclude the suspicion. Staging based on imaging must be carried out in patients newly diagnosed with breast cancer and a clinical suspicion of metastasis. Procedures used for staging must include contrast-enhanced CT (of the thorax, abdomen and pelvis) and a bone scan.	A	Adapted from guideline	[88]
5.6.	PET-CT should only be used if the use of other methods has led to a strong suspicion of distant metastasis in symptomatic patients and this metastasis cannot be reliably confirmed or excluded.	B	Adapted from guideline	[88]

## 3 Follow-up and Long-term Care

Follow-up in the narrow sense of the word consists of structured examinations for loco-regional or intramammary recurrence and contralateral breast cancer, examinations for distant metastasis, investigations which are part of long-term therapy and the diagnosis and treatment of sequelae and side effects. Because of the wide range of therapy regimens, follow-up starts immediately after concluding primary loco-regional therapy [91].

Because different patients have very different risk constellations, a follow-up period of 5 years is not sufficient. This means that even without being directly based on trial data, the follow-up period has been expanded beyond the current period of 5 years to a period of 10 years [92]. It should be noted that therapy must be monitored for at least 10 years.

No.	Recommendations/ Statements	EG	LoE	Sources
6.35.	The follow-up of patients with breast cancer starts once primary loco-regional treatment has been concluded. Follow-up consists of taking the patient's medical history, a physical examination, medical counselling, care and guidance as well as diagnostic imaging procedures to detect local or loco-regional recurrence or contralateral breast cancer. If any of the findings are suspicious, follow-up must take a system-oriented approach.		EC Adapted from guideline	[91, 93 – 100]
6.36.	If required, specialized oncologists and other medical professionals, for example psycho-oncologists, physiotherapists, lymphologists, specialized oncology nurses, breast care nurses, etc., should also be involved in the individual follow-up of breast cancer patients. Depending on the individual requirements of patients, patients should also receive information about further opportunities for counselling and care including information on available self-help support groups.		EC Adapted from guideline	[101, 102]

### 3.1 Examination for loco-regional/intramammary recurrence or contralateral breast cancer

Local/loco-regional recurrence after mastectomy and/or axillary dissection is usually diagnosed by clinical examination. Palpation of the thoracic wall and the lymph drainage areas is therefore a key aspect in all follow-up examinations [103]. The majority of local/loco-regional or intramammary recurrences in affected patients who underwent breast-conserving surgery can be treated curatively.

No.	Recommendations/ Statements	EG	LoE	Sources
6.37.	a) Diagnostic imaging procedures for the detection of local and loco-regional recurrence or contralateral cancer should include an annual mammography and a quality-assured ultrasound examination.	B	2c	[104, 105]
6.38.	b) The addition of quality-assured ultrasound examinations as part of standard follow-up will increase the number of patients who need further investigations and the biopsy rate. The majority of patients (82%) reported that the increased attention and the associated higher security had a psychologically positive impact, with only a few patients (<6%) reporting additional psychological stress due to fear and uncertainty. Ultrasound examinations should therefore only be carried out in addition to mammography.			

### Men with breast cancer

No.	Recommendations/ Statements	EG	LoE	Sources
6.39.	Men with breast cancer must be examined annually using diagnostic imaging procedures in the same way as women with breast cancer, particularly as men have a higher risk of contralateral cancer.	EC		

### 3.2 Examination for metastasis

The 3 most common sites of metastasis for women with breast cancer are the lungs, liver and bones. Depending on the patient's staging, diagnostic procedures are indicated during primary therapy to determine whether metastasis is present. Current prospective studies have shown that intensive follow-up examinations at regular established intervals which include chest X-rays of the lungs, bone scans, ultrasound of the upper abdomen, tumor marker determination and diagnostic CT scans do not provide any additional survival benefit to asymptomatic patients [96, 98].

No.	Recommendations/ Statements	EG	LoE	Sources
6.40.	Intensified diagnostic methods such as chest X-rays, bone scans, CT, PET or MRI and including full blood count tests, serum biochemistry and the determination of tumor markers are used to diagnose metastasis; they are not part of standard follow-up and are only indicated if there are clinical anomalies.	A	1a	[93, 102, 106 – 108]

### 3.3 Diagnosis and treatment of side effects and sequelae from primary and long-term therapy

Follow-up examinations are also used to control and record the success of primary therapy. The overriding principle is that they should contribute to dispelling the patient's fear of disease recurrence. The 10-year probability of survival for patients with favorable tumor features (pT1 N0 M0) is more than 90%.

The sequelae and toxicities from local therapy such as surgery, radiotherapy and systemic therapies such as chemotherapy, targeted therapy, endocrine therapy, osteo-oncologic therapy or complementary and alternative methods (CAM) can be detected and treated, if necessary. More and more breast cancer patients are treated curatively, with therapy administered over longer periods. This has meant that care and support during long-term therapy and the treatment of side effects or late sequelae of therapy are becoming increasingly important. It is important to differentiate between early and late sequelae, between local and systemic side effects and between the long-term side effects of concluded therapies and the acute side effects of current therapies. The affected patient should be informed about therapy-specific short and long-term side effects and possible late sequelae and should be given recommendations about targeted diagnostic and therapeutic treatments or receive treatment where necessary.

The primary local side effects of therapy include edema, somatosensory disorders, chest or breast pain after breast-conserving therapy, limited mobility, and lymphedema [109]. The sequelae (acute and late toxicity) of systemic drug therapies can include myelotoxicity, hepatotoxicity, alopecia, nephrotoxicity, ototoxicity, pulmonary toxicity, cardiotoxicity, infections, thromboembolic events as well as osteoporosis, sterility, climacteric syndrome, secondary cancers, cognitive disorders and more besides [108].

#### Lymphedema

Secondary lymphedema of the arm following breast cancer is a common problem after axillary dissection, with a reported incidence of 20–30% [91, 92]. However, because sentinel lymph node excision is now routinely carried out, lymphedema has become much less common now. Morbidity after treatment can include functional limitations, weight gain and associated impairments affecting the patient's quality of life. Diagnosis and treatment of secondary lymphedema should follow the recommendations given in the interdisciplinary S2k guideline [110].

No.	Recommendations/ Statements	EG	LoE	Sources
6.41.	All patients who undergo axillary lymphadenectomy must be informed about how to recognize the signs of postoperative lymphedema and the prophylactic options and treatment of postoperative lymphedema.	A	1b	[73, 111 – 120]

#### Cardiotoxicity

Anthracyclines and trastuzumab may promote cardiotoxicity [121]. The risk of cardiotoxicity is significantly increased if both substance

classes are combined and administered simultaneously, and this approach is therefore not recommended. Predisposing factors include age, obesity, preexisting congestive heart failure, arterial hypertension, diabetes mellitus, status post myocarditis or myocardial infarction, and left-sided radiation therapy. In the development of acute or chronic myopathies with heart failure, it is important to differentiate between the acute and the sub-acute non-dose-related early forms, the chronic form (within one year) and the late form. Cardiotoxicity can range from decreased left ventricular ejection fraction (LVEF) to clinically relevant chronic heart failure (CHF). Any general decrease in performance or reduction in physical resilience in affected patients should be urgently investigated. It is important to detect any cardiac damage as early as possible to initiate appropriate supportive measures such as targeted therapy to treat heart failure, improve the patient's quality of life and avoid any deterioration of the patient's prognosis [122–124].

### Leukemia

Leukemia is the most common chemotherapy-induced secondary malignancy. The highest risk for secondary leukemia is in the first ten years. The most common type of leukemia is acute myeloid leukemia following the use of anthracyclines [125, 126].

### Climacteric syndrome

Chemotherapy and endocrine systemic therapy can induce climacteric syndrome in premenopausal/perimenopausal patients or intensify the symptoms in postmenopausal patients [127]. How patients experience symptoms is subjective and can differ considerably; it may also depend on the time of onset and the duration of amenorrhea as well as the duration of therapy, particularly of endocrine therapy. Treatment of the symptoms of climacteric syndrome depends on the symptoms experienced. Hormone therapy is contraindicated after breast cancer. Hormone therapy is therefore only prescribed in very exceptional cases, and is discussed with great reluctance and only considered when patients report a serious impairment of their quality of life. According to the data from current studies, hormone therapy is contraindicated in hormone receptor-positive breast cancer patients [128].

### Thromboembolic events

Thromboembolic events which take the form of paraneoplastic syndrome can occur during primary therapy. They are often an indication of more extensive tumors or metastasis [129]. Thromboembolic events can occur in patients receiving systemic endocrine therapy, particularly during or after long-term therapy [130]. The diagnosis and therapy of thrombosis and arterial lung embolism and the appropriate prophylactic measures are described in the interdisciplinary S2 and S3 guidelines of other professional societies (AWMF 065/002).

### Osteoporosis

Estrogens are among the most important factors regulating bone metabolism. Physiologically, bone mass reduction starts with the commencement of menopause. Therapy may reinforce this process, either because chemotherapy or systemic endocrine therapy triggers premature menopause in premenopausal patients or because the use of aromatase inhibitors in postmenopausal patients

intensifies the process of bone reduction. Patients with a significantly higher risk of developing osteoporosis or who already known to have osteoporosis should be recommended the appropriate medication as outlined in the S3 guideline of the DVO (German Osteology Organization); patients who have not yet developed osteoporosis should be informed about appropriate behavioral measures such as physical exercise, modifications of their diet, and substitution with Vitamin D and possibly calcium, if needed [108, 131–133]. Patients should receive detailed information about the options for osteo-oncologic medication. It is important in all cases to determine the risk of fractures early on by carrying out a DEXA scan to measure bone density before and during any potentially necessary anti-hormone therapy or scheduled chemotherapy.

### Fatigue

Patients with chronic fatigue syndrome after treatment for breast cancer must be given information about physical exercise strategies and psychosocial support [134, 135].

### Reproduction

Premenopausal breast cancer patients wanting to have children should be informed before and after the successful conclusion of primary breast cancer therapy about the options of preserving fertility and having children [136]. To date, no study has confirmed the originally expected increase in the risk of recurrence arising from endocrine changes occurring during pregnancy [137]. The survival benefit postulated in some studies for patients who became pregnant some years after successful treatment for breast cancer is probably due to a “healthy mother effect” [136, 138]. The basic principle is that any decision for or against having children after concluding primary therapy for breast cancer should be based on personal lifestyle considerations and less on vague medical hypotheses. If preventing pregnancy is indicated, either for medical reasons, for example in the context of endocrine therapy, or because of personal lifestyle choices, contraception should generally not consist of hormonal birth control. The risks associated with hormonal contraception must be weighed up carefully.

## 3.4 Frequency of follow-up

A follow-up period of at least ten years is necessary because of the tumor biology of breast cancer [91, 139]. Therapy monitoring must be continued for at least 10 years.

No.	Recommendations/ Statements	EG	LoE	Sources
6.43.	In the first 3 years after concluding primary local therapy, patients should have a follow-up examination every 3 months; in the 4th and 5th year, patients should be followed up bi-annually and in the 6th year and thereafter, patients should have an annual follow-up examination. This includes annual screening.	EC		



## Follow-up examinations after breast cancer

Years after primary therapy	Follow-up		Screening
	1st–3rd year	4th and 5th year	6 years and more
Medical history Physical examination Counselling/information	Every 3 months	Twice a year	Annually
Laboratory examinations, examinations using imaging procedures (exceptions: mammography and breast ultrasound)	Only if there is a clinical suspicion of recurrence and/or metastasis		

## Follow-up examinations for breast cancer – breast diagnostics after BCT and mastectomy

Years after primary therapy	Year 1 – Year 3	From Year 4
Ipsilateral breast (BCT): mammography, breast sonography Mastectomy: ultrasound	At least once a year	Annually
Contralateral breast: mammography, ultrasound if required	Annually	Annually

No.	Recommendations/ Statements	EG	LoE	Sources
6.44.	During follow-up, patients should be encouraged to do physical exercise (> 2–3 h/ week) and to normalize their body weight (in patients with a high BMI). Patients should be offered support to do so.	EC		
6.45.	Constant motivation of the patient to regularly take the medication prescribed for adjuvant therapy, particularly endocrine therapy (e.g. tamoxifen or aromatase inhibitors), is an essential part of follow-up care. The patient must be questioned in detail about how well she tolerates the therapy and about any side effects. Appropriate measures must be taken to treat any complaints. Premature discontinuation of therapy can be prevented by changing the endocrine therapy.	EC		

## 5 Rehabilitation

No.	Recommendation	EG	LoE	Sources
6.46.	Tumor disease and treatment of disease with surgery, radiation therapy and systemic therapy can lead to disorders of varying severity, which require targeted rehabilitative somatic and psychosocial measures. Patients must be informed early on about options for outpatient and inpatient rehabilitation as well as about other forms of support to which they are entitled under German social law. When prescribing rehabilitative measures, the patient's own wishes must be considered when recommending the type of rehabilitation.	EC		

## 6 Palliative Medicine

The development of care structures and the inclusion of palliative medicine into medical training and further training has made it possible for patients with incurable disease and a limited or uncertain prognosis to access palliative care which complements oncologic therapy (Reference: Leitlinienprogramm Onkologie [Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF]: Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung [Palliative Medicine for Patients with Incurable Cancer], long version 1.1, 2015, AWMF registry number: 128/001OL, <http://leitlinienprogramm.onkologie.de/Palliativmedizin.80.0.html>).

No.	Recommendations/ Statements	EG	LoE	Sources
5.42.	The principles listed below must be followed when offering palliative care to patients with incurable breast cancer: 1. The patient's needs must be considered and addressed on all four levels (physical, psychological, social, and spiritual). 2. The patient's needs must be taken into account. 3. Realistic treatment goals must be defined. 4. The patient must be informed about the different ways in which palliative care is organized. 5. An environment must be created which respects the patient's intimacy.	EC		

## Conflict of Interest

See guideline report: [https://www.awmf.org/uploads/tx\\_szleitlinien/032-045OLm\\_S3\\_Mammakarzinom\\_2017-12.pdf](https://www.awmf.org/uploads/tx_szleitlinien/032-045OLm_S3_Mammakarzinom_2017-12.pdf)

## References

- [1] Albert US, Altland H, Duda V. Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland. München: Zuckschwerdt; 2008
- [2] Duke Evidence Synthesis Group Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines. Guidelines Development Group. Durham, NC: Duke Clinical Research Institute; 2014
- [3] WHO. WHO position paper on mammography screening. Geneva: World Health Organization; 2014
- [4] Broeders M, Moss S, Nyström L et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen* 2012; 19 (Suppl. 1): 14–25
- [5] Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. *N Engl J Med* 2012; 367: 1998–2005
- [6] Helvie MA, Chang JT, Hendrick RE et al. Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer. *Cancer* 2014; 120: 2649–2656
- [7] European Commission Initiative on Breast Cancer (ECIBC). Evidence report update (2016). Online: <http://ecibc.jrc.ec.europa.eu/recommendations/list/3>
- [8] Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med* 2016; 164: 279–296
- [9] International Agency for Research on Cancer (IARC). Breast Cancer Screening. IARC Handbook of Cancer Prevention. 2016
- [10] Lauby-Secretan B, Scoccianti C, Loomis D et al. Body Fatness and Cancer – Viewpoint of the IARC Working Group. *N Engl J Med* 2016; 375: 794–798
- [11] Myers ER, Moorman P, Gierisch JM et al. Benefits and Harms of Breast Cancer Screening: A Systematic Review. *JAMA* 2015; 314: 1615–1634
- [12] Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. *JAMA* 2014; 311: 1327–1335
- [13] Nelson HD, Fu R, Cantor A et al. Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med* 2016; 164: 244–255
- [14] Moss SM, Hale C, Smith R et al. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. *Lancet Oncol* 2015; 16: 1123–1132
- [15] Houssami N, Abraham LA, Kerlikowske K et al. Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. *Cancer Epidemiol Biomarkers Prev* 2013; 22: 946–961
- [16] Kerlikowske K, Zhu W, Tosteson AN et al. Identifying women with dense breasts at high risk for interval cancer: a cohort study. *Ann Intern Med* 2015; 162: 673–681
- [17] Brentnall AR, Harkness EF, Astley SM et al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. *Breast Cancer Res* 2015; 17: 147
- [18] Hodgson R, Heywang-Köbrunner SH, Harvey SC et al. Systematic review of 3D mammography for breast cancer screening. *Breast* 2016; 27: 52–61
- [19] Melnikow J, Fenton JJ, Whitlock EP et al. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2016; 164: 268–278
- [20] Ohuchi N, Suzuki A, Sobue T et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. *Lancet* 2016; 387: 341–348
- [21] Tagliafico AS, Calabrese M, Mariscotti G et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial. *J Clin Oncol* 2016; 34: 1882–1888
- [22] Skaane P, Bandos AI, Eben EB et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. *Radiology* 2014; 271: 655–663
- [23] Lång K, Andersson I, Rosso A et al. Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. *Eur Radiol* 2016; 26: 184–190
- [24] Caumo F, Bernardi D, Ciatto S et al. Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: increased breast cancer detection evident for screening centres in a population-based trial. *Breast* 2014; 23: 76–80
- [25] Kast K, Rhiem K, Wappenschmidt B et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. *J Med Genet* 2016; 53: 465–471
- [26] National Institute for Health and Care Excellence (NICE). Familial Breast Cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2015). Online: <https://www.nice.org.uk/guidance/cg164>
- [27] Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014; 160: 271–281
- [28] Légaré F, Stacey D, Turcotte S et al. Interventions for improving the adoption of shared decision making by healthcare professionals. *Cochrane Database Syst Rev* 2014; (9): CD006732
- [29] Stacey D, Légaré F, Lewis K et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev* 2014; (1): CD001431
- [30] Stacey D, Samant R, Bennett C. Decision making in oncology: a review of patient decision aids to support patient participation. *CA Cancer J Clin* 2008; 58: 293–304
- [31] Kopke S, Gerlach A. [Informed decisions]. *Pflege Z* 2012; 65: 220–223
- [32] Mühlhauser I, Steckelberg A. Evidenzbasierte Patienteninformation: Wünsche der Betroffenen. *Deutsches Ärzteblatt* 2009; 106: A2554–A2556
- [33] Lühnen J, Albrecht M, Mühlhauser I, Steckelberg A. Leitlinie evidenzbasierte Gesundheitsinformation. Hamburg 2017. Online: <http://www.leitlinie-gesundheitsinformation.de/>
- [34] Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. *Pharmgenomics Pers Med* 2014; 7: 307–316
- [35] Byrski T, Huzarski T, Dent R et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. *Breast Cancer Res Treat* 2014; 147: 401–405
- [36] Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. *J Clin Oncol* 2010; 28: 375–379
- [37] Liu M, Mo QG, Wei CY et al. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. *Oncol Lett* 2013; 5: 983–991
- [38] Telli M. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. *Am Soc Clin Oncol Educ Book* 2014: e37–e42
- [39] Turner NC, Tutt AN. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? *Breast Cancer Res* 2012; 14: 115

- [40] Li X, You R, Wang X et al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. *Clin Cancer Res* 2016; 22: 3971–3981
- [41] De Felice F, Marchetti C, Musella A et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. *Ann Surg Oncol* 2015; 22: 2876–2880
- [42] Domchek SM, Friebel TM, Singer CF et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA* 2010; 304: 967–975
- [43] Evans DG, Ingham SL, Baildam A et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. *Breast Cancer Res Treat* 2013; 140: 135–142
- [44] Lindor NM, Goldgar DE, Tavtigian SV et al. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. *Oncologist* 2013; 18: 518–524
- [45] Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. *Ann Oncol* 2013; 24: 2029–2035
- [46] Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. *Cochrane Database Syst Rev* 2010; (11): CD002748
- [47] Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2001; 345: 159–164
- [48] Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 2004; 22: 1055–1062
- [49] Evans DG, Clayton R, Donnai P et al. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. *Eur J Hum Genet* 2009; 17: 1381–1385
- [50] Kauff ND, Domchek SM, Friebel TM et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *J Clin Oncol* 2008; 26: 1331–1337
- [51] Kotsopoulos J, Huzarski T, Gronwald J et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2017; 109: pii: djw177. doi:10.1093/jnci/djw177
- [52] Fakkert IE, Mourits MJ, Jansen L et al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. *Cancer Prev Res (Phila)* 2012; 5: 1291–1297
- [53] Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2004; 22: 2328–2335
- [54] Graeser MK, Engel C, Rhiem K et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2009; 27: 5887–5892
- [55] Rhiem K, Engel C, Graeser M et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. *Breast Cancer Res* 2012; 14: R156
- [56] Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. *Int J Cancer* 2015; 136: 668–677
- [57] van den Broek AJ, van 't Veer LJ, Hoening MJ et al. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. *J Clin Oncol* 2016; 34: 409–418
- [58] Marchetti C, De Felice F, Palaia I et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. *BMC Womens Health* 2014; 14: 150
- [59] Metcalfe K, Lynch HT, Foulkes WD et al. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. *JAMA Oncol* 2015; 1: 306–313
- [60] Plon SE, Eccles DM, Easton D et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum Mutat* 2008; 29: 1282–1291
- [61] Boughey JC, Hoskin TL, Degnim AC et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. *Ann Surg Oncol* 2010; 17: 2702–2709
- [62] Fayanju OM, Stoll CR, Fowler S et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. *Ann Surg* 2014; 260: 1000–1010
- [63] Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. *Maturitas* 2002; 41: 171–175
- [64] Morrow M, Chatterton RT jr., Rademaker AW et al. A prospective study of variability in mammographic density during the menstrual cycle. *Breast Cancer Res Treat* 2010; 121: 565–574
- [65] Scaranelo AM, Carrillo MC, Fleming R et al. Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density. *Radiology* 2013; 267: 692–700
- [66] Chiarelli AM, Prummel MV, Muradali D et al. Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection. *Breast Cancer Res Treat* 2015; 154: 377–387
- [67] Nothacker M, Duda V, Hahn M et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. *BMC Cancer* 2009; 9: 335
- [68] New Zealand Guidelines Group (NZGG). Management of Early Breast Cancer – Evidence-based Best Practice Guideline. New Zealand Guidelines Group (2009). Online: <https://www.health.govt.nz/system/files/documents/publications/mgmt-of-early-breast-cancer-aug09.pdf>; last access: 01.09.2016
- [69] Berg WA, Bandos AI, Mendelson EB et al. Ultrasound as the Primary Screening Test for Breast Cancer: Analysis From ACRIN 6666. *J Natl Cancer Inst* 2016; 108: pii: djv367. doi:10.1093/jnci/djv367
- [70] Houssami N, Irwig L, Simpson JM et al. Sydney Breast Imaging Accuracy Study: Comparative sensitivity and specificity of mammography and sonography in young women with symptoms. *AJR Am J Roentgenol* 2003; 180: 935–940
- [71] Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. *Radiology* 2002; 225: 165–175
- [72] Müller-Schimpfle M, Graf O, Madjar H et al. Diskussionspapier – BI-RADS die 5. – eine Kurzmitteilung aus deutsch-/österreichischer Sicht. *Rofo* 2016; 188: 346–352
- [73] National Institute for Health and Care Excellence (NICE). The National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment (2009 [addendum 2014]). Online: <https://www.nice.org.uk/guidance/cg81/evidence/addendum-242246990>
- [74] Bennani-Baiti B, Bennani-Baiti N, Baltzer PA. Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis. *PLoS One* 2016; 11: e0160346
- [75] Fancellu A, Turner RM, Dixon JM et al. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. *Br J Surg* 2015; 102: 883–893
- [76] Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. *Ann Surg* 2013; 257: 249–255

- [77] Plana MN, Carreira C, Muriel A et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis. *Eur Radiol* 2012; 22: 26–38
- [78] Elkin EB, Kim SH, Casper ES et al. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. *J Clin Oncol* 2007; 25: 5275–5280
- [79] Dahabreh IJ, Wieland LS, Adam GP, Halladay C, Lau J, Trikalinos TA. AHRQ Comparative Effectiveness Reviews, in Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions: An Update to the 2009 Report. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014
- [80] Ahn HS, Kim SM, Jang M et al. Comparison of sonography with sonographically guided fine-needle aspiration biopsy and core-needle biopsy for initial axillary staging of breast cancer. *J Ultrasound Med* 2013; 32: 2177–2184
- [81] Ganott MA, Zuley ML, Abrams GS et al. Ultrasound Guided Core Biopsy versus Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients with Breast Cancer. *ISRN Oncol* 2014; 2014: 703160
- [82] Rao R, Lilley L, Andrews V et al. Axillary staging by percutaneous biopsy: sensitivity of fine-needle aspiration versus core needle biopsy. *Ann Surg Oncol* 2009; 16: 1170–1175
- [83] Rautiainen S, Masarwah A, Sudah M et al. Axillary lymph node biopsy in newly diagnosed invasive breast cancer: comparative accuracy of fine-needle aspiration biopsy versus core-needle biopsy. *Radiology* 2013; 269: 54–60
- [84] Bolívar AV, Alonso-Bartolomé P, García EO et al. Ultrasound-guided core needle biopsy of non-palpable breast lesions: a prospective analysis in 204 cases. *Acta Radiol* 2005; 46: 690–695
- [85] Fishman JE, Milikowski C, Ramsinghani R et al. US-guided core-needle biopsy of the breast: how many specimens are necessary? *Radiology* 2003; 226: 779–782
- [86] Schulz-Wendtland R, Aichinger U, Krämer S et al. [Sonographical breast biopsy: how many core biopsy specimens are needed?]. *Rofo* 2003; 175: 94–98
- [87] Bruening W, Fontanarosa J, Tipton K et al. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. *Ann Intern Med* 2010; 152: 238–246
- [88] Department of Health. Diagnosis, staging and treatment of patients with breast cancer. National Clinical Guideline No. 7. June 2015. ISSN 2009-6259. Online: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/guidelines/breast/>; last access: May 2016
- [89] Runowicz CD, Leach CR, Henry NL et al. American Cancer society/American society of clinical oncology breast Cancer survivorship care guideline. *CA Cancer J Clin* 2016; 66: 43–73
- [90] Shah C, Ahlawat S, Khan A et al. The Role of MRI in the Follow-up of Women Undergoing Breast-conserving Therapy. *Am J Clin Oncol* 2016; 39: 314–319
- [91] Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. *J Clin Oncol* 2006; 24: 5091–5097
- [92] Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. *J Clin Oncol* 1996; 14: 2738–2746
- [93] Rojas MP, Telaro E, Russo A et al. Follow-up strategies for women treated for early breast cancer. *Cochrane Database Syst Rev* 2000; (4): CD001768
- [94] Gulliford T, Opomu M, Wilson E et al. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hot-line study. *BMJ* 1997; 314: 174–177
- [95] Hurria A, Hudis C. Follow-up care of breast cancer survivors. *Crit Rev Oncol Hematol* 2003; 48: 89–99
- [96] Palli D, Russo A, Saieva C et al. Intensive vs. clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. *JAMA* 1999; 281: 1586
- [97] Pestalozzi BC, Luporsi-Gely E, Jost LM et al. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. *Ann Oncol* 2005; 16 (Suppl. 1): i7–i9
- [98] Rosselli Del Turco M, Palli D, Cariddi A et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. *JAMA* 1994; 271: 1593–1597
- [99] Ferzoco RM, Ruddy KJ. Optimal delivery of male breast cancer follow-up care: improving outcomes. *Breast Cancer (Dove Med Press)* 2015; 7: 371–379
- [100] Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Supportive Therapie bei onkologischen PatientInnen-Konsultationsfassung, Langversion, 2016, AWMF Registernummer: 032-054OL. Online: <http://leitlinienprogramm-onkologie.de/Supportive-Therapie.95.0.html>; last access: 13.10.2016
- [101] Selby P, Gillis C, Haward R. Benefits from specialised cancer care. *Lancet* 1996; 348: 313–318
- [102] National Breast and Ovarian Cancer Centre. Recommendations for follow-up of women with early breast cancer. Surry Hills: NSW; 2010. Online: [https://guidelines.canceraustralia.gov.au/guidelines/early\\_breast\\_cancer/](https://guidelines.canceraustralia.gov.au/guidelines/early_breast_cancer/)
- [103] Dalberg K, Mattsson A, Sandelin K et al. Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer. *Breast Cancer Res Treat* 1998; 49: 69–78
- [104] Riebe E, Günther K, Schulz K et al. Recurrent disease after breast preserving therapy (BPT) and radiation therapy for breast cancer – diagnostic yield of palpation, mammography and ultrasonography. *Ultraschall Med* 2007; 28: 394–400
- [105] Wojcinski S, Farrokh A, Hille U et al. Optimizing breast cancer follow-up: diagnostic value and costs of additional routine breast ultrasound. *Ultrasound Med Biol* 2011; 37: 198–206
- [106] Aguiar-Bujanda D, Bohn-Sarmiento U, Aguiar-Morales J. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer. *Breast J* 2004; 10: 375–376
- [107] Bornhak S, Heidemann E, Herschlein HJ et al. Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study. *Onkologie* 2007; 30: 443–449
- [108] Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. *N Engl J Med* 2007; 356: 2505–2513
- [109] Brennan MJ. Lymphedema following the surgical treatment of breast cancer: a review of pathophysiology and treatment. *J Pain Symptom Manage* 1992; 7: 110–116
- [110] Gesellschaft Deutschsprachiger Lymphologen (GDL). S2 k-Leitlinie Diagnostik und Therapie der Lymphödeme, AWMF Registernummer: 058-001. Online: [http://www.awmf.org/uploads/tx\\_szleitlinien/058-001\\_S2k\\_Diagnostik\\_und\\_Therapie\\_der\\_Lymphoedeme\\_2017-05.pdf](http://www.awmf.org/uploads/tx_szleitlinien/058-001_S2k_Diagnostik_und_Therapie_der_Lymphoedeme_2017-05.pdf)
- [111] Armer J, Fu MR, Wainstock JM et al. Lymphedema following breast cancer treatment, including sentinel lymph node biopsy. *Lymphology* 2004; 37: 73–91
- [112] Bani HA, Fasching PA, Lux MM et al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. *Patient Educ Couns* 2007; 66: 311–318
- [113] Francis WP, Abghari P, Du W et al. Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. *Am J Surg* 2006; 192: 636–639

- [114] Golshan M, Martin WJ, Dowlatshahi K. Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. *Am Surg* 2003; 69: 209–211; discussion 212
- [115] Hamner JB, Fleming MD. Lymphedema therapy reduces the volume of edema and pain in patients with breast cancer. *Ann Surg Oncol* 2007; 14: 1904–1908
- [116] Harris SR, Hugi MR, Olivotto IA et al. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. *CMAJ* 2001; 164: 191–199
- [117] Hayes S, Cornish B, Newman B. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. *Breast Cancer Res Treat* 2005; 89: 221–226
- [118] Moseley AL, Carati CJ, Piller NB. A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment. *Ann Oncol* 2007; 18: 639–646
- [119] Sanjuán A, Vidal-Sicart S, Zanón G et al. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients. *Eur J Nucl Med Mol Imaging* 2005; 32: 932–936
- [120] Torrens H, Fabry H, van der Sijp JR et al. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. *J Surg Oncol* 2004; 88: 4–7; discussion 7–8
- [121] Bonnetterre J, Roché H, Kerbrat P et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. *J Clin Oncol* 2004; 22: 3070–3079
- [122] Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. *Semin Oncol* 2006; 33 (3 Suppl. 8): S15–S21
- [123] Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. *J Clin Oncol* 2004; 22: 322–329
- [124] Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. *J Clin Oncol* 2005; 23: 7811–7819
- [125] Le Deley MC, Suzan F, Cutuli B et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. *J Clin Oncol* 2007; 25: 292–300
- [126] Smith RE. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. *Clin Breast Cancer* 2003; 4: 273–279
- [127] Mom CH, Buijs C, Willemse PH et al. Hot flushes in breast cancer patients. *Crit Rev Oncol Hematol* 2006; 57: 63–77
- [128] Pritchard KI, Khan H, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. *CMAJ* 2002; 166: 1017–1022
- [129] Caine GJ, Stonelake PS, Rea D et al. Coagulopathic complications in breast cancer. *Cancer* 2003; 98: 1578–1586
- [130] Gail MH, Costantino JP, Bryant J et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *J Natl Cancer Inst* 1999; 91: 1829–1846
- [131] Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 2003; 21: 4042–4057
- [132] Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. *J Clin Oncol* 2005; 23: 619–629
- [133] Dachverband Osteologie. Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern, Langversion, 2017, AWMF-Registernummer: 183/001. Online: [http://www.dvo-osteologie.org/dvo\\_leitlinien/dvo-leitlinie-2017](http://www.dvo-osteologie.org/dvo_leitlinien/dvo-leitlinie-2017)
- [134] Edmonds M, McGuire H, Price J. Exercise therapy for chronic fatigue syndrome. *Cochrane Database Syst Rev* 2004; (3): CD003200
- [135] Servaes P, Prins J, Verhagen S et al. Fatigue after breast cancer and in chronic fatigue syndrome: similarities and differences. *J Psychosom Res* 2002; 52: 453–459
- [136] Petrek J, Seltzer V. Breast cancer in pregnant and postpartum women. *J Obstet Gynaecol Can* 2003; 25: 944–950
- [137] Velentgas P, Daling JR, Malone KE et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. *Cancer* 1999; 85: 2424–2432
- [138] Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect”. *Am J Obstet Gynecol* 1994; 170: 818–823
- [139] Donnelly J, Mack P, Donaldson LA. Follow-up of breast cancer: time for a new approach? *Int J Clin Pract* 2001; 55: 431–433

## Guideline Program

### Editors

#### Leading Professional Medical Associations



**German Society of Gynecology and Obstetrics  
(Deutsche Gesellschaft für Gynäkologie  
und Geburtshilfe e. V. [DGOG])**

Head Office of DGOG and Professional Societies  
Hausvogteiplatz 12, DE-10117 Berlin  
info@dogg.de  
<http://www.dogg.de/>

#### President of DGOG

Prof. Dr. Birgit Seelbach-Göbel  
Universität Regensburg  
Klinik für Geburtshilfe und Frauenheilkunde  
St. Hedwig-Krankenhaus Barmherzige Brüder  
Steinmetzstraße 1–3, DE-93049 Regensburg

#### DGOG Guidelines Representatives

Prof. Dr. med. Matthias W. Beckmann  
Universitätsklinikum Erlangen, Frauenklinik  
Universitätsstraße 21–23, DE-91054 Erlangen

Prof. Dr. med. Erich-Franz Solomayer  
Universitätsklinikum des Saarlandes  
Geburtshilfe und Reproduktionsmedizin  
Kirrberger Straße, Gebäude 9, DE-66421 Homburg

#### Guidelines Coordination

Dr. med. Paul Gaß, Christina Meixner  
Universitätsklinikum Erlangen, Frauenklinik  
Universitätsstraße 21–23, DE-91054 Erlangen  
fk-dogg-leitlinien@uk-erlangen.de  
<http://www.dogg.de/leitlinienstellungennahmen>



**Austrian Society of Gynecology and Obstetrics  
(Österreichische Gesellschaft für Gynäkologie  
und Geburtshilfe [OEGGG])**

Innrain 66A, AT-6020 Innsbruck  
stephanie.leutgeb@oeggg.at  
<http://www.oeggg.at>

#### President of OEGGG

Prof. Dr. med. Petra Kohlberger  
Universitätsklinik für Frauenheilkunde Wien  
Währinger Gürtel 18–20, AT-1180 Wien

#### OEGGG Guidelines Representatives

Prof. Dr. med. Karl Tamussino  
Universitätsklinik für Frauenheilkunde und Geburtshilfe Graz  
Auenbruggerplatz 14, AT-8036 Graz

Prof. Dr. med. Hanns Helmer  
Universitätsklinik für Frauenheilkunde Wien  
Währinger Gürtel 18–20, AT-1090 Wien



**Swiss Society of Gynecology and Obstetrics  
(Schweizerische Gesellschaft für Gynäkologie  
und Geburtshilfe [SGGG])**

Gynécologie Suisse SGGG  
Altenbergstraße 29, Postfach 6, CH-3000 Bern 8  
sekretariat@sogg.ch  
<http://www.sogg.ch/>

#### President of SGGG

Dr. med. David Ehm  
FMH für Geburtshilfe und Gynäkologie  
Nägeligasse 13, CH-3011 Bern

#### SGGG Guidelines Representatives

Prof. Dr. med. Daniel Surbek  
Universitätsklinik für Frauenheilkunde  
Geburtshilfe und feto-maternale Medizin  
Inselspital Bern  
Effingerstraße 102, CH-3010 Bern

Prof. Dr. med. René Hornung  
Kantonsspital St. Gallen, Frauenklinik  
Rorschacher Straße 95, CH-9007 St. Gallen